Guanfacine hydrochloride
SIGMA/G1043 - ≥98% (HPLC)
Synonym: N (Aminoiminomethyl)
CAS Number: 29110-48-3
Empirical Formula (Hill Notation): C9H9Cl2N3O · HCl
Molecular Weight: 282.55
MDL Number: MFCD00798230
Linear Formula: C9H9Cl2N3O · HCl
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white |
| InChI | 1S/C9H9Cl2N3O.ClH/c10-6-2 |
| InChI key | DGFYECXYGUIODH-UHFFFAOYSA |
| originator | Promius |
| Quality Level | 100 ![]() |
| SMILES string | Cl.NC(=N)NC(=O)Cc1c(Cl)cc |
| solubility | H2O: soluble 12 mg/mL at 60 °C |
| Application: | Guanfacine hydrochloride has been used as an α2A adrenoceptor agonist to test its protective effect on hypobaric hypoxia (HH) and in rat brain to measure blood oxygenation level dependent (BOLD) response. |
| Biochem/physiol Actions: | α-2 noradrenergic receptor agonist. |
| Biochem/physiol Actions: | Guanfacine stimulates the brain postsynaptic α2 adrenergic receptor (AR) and mediates the prefrontal cortical (PFC) neuronal regulation and strengthens their network. Guanfacine improves the density of neuronal dendrites and is useful in treating neuropsychiatric disorders. It modulates the synaptic and cytoskeletal proteins expression in prefrontal cortical (PFC) neurons and may improve hypobaric hypoxia (HH) induced PFC dysfunctions. Guanfacine enhances cognitive function and is recommended for attention deficit hyperactivity disorder (ADHD) therapy. |
| Features and Benefits: | This compound was developed by Promius . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| UNSPSC | 12352200 |

